London
· Delayed Price · Currency is GBP · Price in USDAlnylam Pharmaceuticals Statistics
Total Valuation
Alnylam Pharmaceuticals has a market cap or net worth of GBP 25.18 billion. The enterprise value is 25.14 billion.
| Market Cap | 25.18B |
| Enterprise Value | 25.14B |
Important Dates
The next estimated earnings date is Thursday, February 20, 2025.
| Earnings Date | Feb 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.97% |
| Shares Change (QoQ) | +1.47% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 128.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 1,043.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -101.40 |
| EV / Sales | 15.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 2,097.42 |
Financial Position
The company has a current ratio of 2.75, with a Debt / Equity ratio of 84.26.
| Current Ratio | 2.75 |
| Quick Ratio | 2.57 |
| Debt / Equity | 84.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | 169.72 |
| Interest Coverage | -1.40 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -2.92% |
| Return on Capital (ROIC) | -4.47% |
| Revenue Per Employee | 744,251 |
| Profits Per Employee | -118,049 |
| Employee Count | 2,100 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 3.57 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +27.89% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +27.89% |
| 50-Day Moving Average | 264.16 |
| 200-Day Moving Average | 221.77 |
| Relative Strength Index (RSI) | 41.10 |
| Average Volume (20 Days) | 1,153 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.34 |
Income Statement
In the last 12 months, Alnylam Pharmaceuticals had revenue of GBP 1.56 billion and -247.90 million in losses. Loss per share was -1.96.
| Revenue | 1.56B |
| Gross Profit | 1.33B |
| Operating Income | -140.36M |
| Pretax Income | -239.58M |
| Net Income | -247.90M |
| EBITDA | -98.59M |
| EBIT | -140.36M |
| Loss Per Share | -1.96 |
Balance Sheet
The company has 2.07 billion in cash and 2.03 billion in debt, giving a net cash position of 40.32 million.
| Cash & Cash Equivalents | 2.07B |
| Total Debt | 2.03B |
| Net Cash | 40.32M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 24.14M |
| Book Value Per Share | 0.19 |
| Working Capital | 1.59B |
Cash Flow
In the last 12 months, operating cash flow was 42.20 million and capital expenditures -30.21 million, giving a free cash flow of 11.98 million.
| Operating Cash Flow | 42.20M |
| Capital Expenditures | -30.21M |
| Free Cash Flow | 11.98M |
| FCF Per Share | n/a |
Margins
Gross margin is 85.37%, with operating and profit margins of -8.98% and -15.86%.
| Gross Margin | 85.37% |
| Operating Margin | -8.98% |
| Pretax Margin | -15.33% |
| Profit Margin | -15.86% |
| EBITDA Margin | -6.31% |
| EBIT Margin | -8.98% |
| FCF Margin | 0.77% |
Dividends & Yields
Alnylam Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.97% |
| Shareholder Yield | -1.97% |
| Earnings Yield | -1.00% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Alnylam Pharmaceuticals has an Altman Z-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2 |
| Piotroski F-Score | n/a |